PDCD1 and neoplasm: The fusion of IL-21 to anti-PD-1 antibody demonstrated potent anti-tumour effects in established tumour-bearing mice, accompanied with an increased frequency of Tscm-cells and expansion of tumour-specific CD8+ Tem-cells which was superior to a combination of PD-1 blockade and IL-21 infusion [78].